Actinium Pharmaceuticals Reports $35 Million Revenue and $27.9 Million Net Income for Q2 2026

Actinium Pharmaceuticals, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recognized total revenue of $35 million, attributed to the recognition of previously deferred revenue from a licensing agreement with Immedica Pharma AB. This marks a substantial turnaround from the same period in 2025, when the company reported no revenue. The net income for the quarter was $27.9 million, a notable increase from a net loss of $6.9 million in the prior year, primarily driven by the recognition of the $35 million upfront payment.

In terms of operating expenses, Actinium reported a total of $7.4 million for the three months ended June 30, 2026, slightly down from $7.5 million in the same period last year. Research and development expenses increased to $5.4 million from $4.9 million, reflecting higher preclinical and clinical costs. General and administrative expenses decreased to $2.1 million, down from $2.6 million, due to lower compensation costs following a workforce reduction in 2025. The company’s interest income also saw a decline, totaling $0.3 million compared to $0.6 million in the previous year, attributed to a lower average cash balance.

Actinium's balance sheet showed total assets of $40.2 million as of June 30, 2026, down from $51.8 million at the end of 2025. The decrease in cash and cash equivalents was notable, dropping to $36.5 million from $48.3 million. However, stockholders' equity increased significantly to $30.3 million, up from $7.8 million at the end of 2025, reflecting the company's improved financial position following the revenue recognition.

The company continues to focus on its clinical-stage biopharmaceutical initiatives, particularly in developing targeted radiotherapies for oncology. Actinium is advancing its lead product candidate, ATNM-400, which targets a novel antigen across multiple solid tumor types. The company is also preparing for the operational launch of its new radiopharmaceutical manufacturing facility, expected to be completed in the second half of 2026. Actinium anticipates reporting data from ongoing clinical studies for ATNM-400 and other candidates in late 2026 and throughout 2027.

Looking ahead, Actinium is optimistic about its growth trajectory, bolstered by the recent revenue recognition and ongoing clinical developments. The company is actively seeking strategic partnerships to enhance its clinical programs and expand its market presence. However, it remains cautious about potential risks, including compliance with NYSE listing standards and the impact of broader economic conditions on its operations.